Evidence map›Paper›PMID 39249163›Full record

ArticleClinical and experimental medicine2024

Toxicity profiles of immune checkpoint inhibitors in nervous system cancer: a comprehensive disproportionality analysis using FDA adverse event reporting system.

Rongrong Liu, Hui Zhao, Zenghong Lu, Lingshuai Zeng, Huaqiu Shi, Longqiu Wu, Jing Wang, Fangjun Zhong, Chuanjian Liu, Yu Zhang and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical and experimental medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Rongrong LiuDepartment of Neurology, The First Affiliated Hospital of Gannan Medical University, Ganzhou, Jiangxi, China.
Hui ZhaoDepartment of Sleep Medicine, Ganzhou People's Hospital, Ganzhou, Jiangxi, China.
Zenghong LuDepartment of Oncology, The First Affiliated Hospital of Gannan Medical University, Ganzhou, Jiangxi, China.
Lingshuai ZengMajor of Rehabilitation, Faculty of Medicine, Jinggangshan University, Ji'an, Jiangxi, China.
Huaqiu ShiDepartment of Oncology, The First Affiliated Hospital of Gannan Medical University, Ganzhou, Jiangxi, China.
Longqiu WuDepartment of Oncology, The First Affiliated Hospital of Gannan Medical University, Ganzhou, Jiangxi, China.
Jing WangDepartment of Oncology, The First Affiliated Hospital of Gannan Medical University, Ganzhou, Jiangxi, China.
Fangjun ZhongDepartment of Neurology, The First Affiliated Hospital of Gannan Medical University, Ganzhou, Jiangxi, China.
Chuanjian LiuDepartment of Oncology, The First Affiliated Hospital of Gannan Medical University, Ganzhou, Jiangxi, China.
Yu ZhangDepartment of Neurology, The First Affiliated Hospital of Gannan Medical University, Ganzhou, Jiangxi, China. 3447159507@qq.com.
Zhengang QiuDepartment of Neurology, The First Affiliated Hospital of Gannan Medical University, Ganzhou, Jiangxi, China. qiuzhengang@gmu.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundImmune-related adverse events (irAEs) always occur during treatment with immune checkpoint inhibitors (ICIs). Patients with nervous system cancer (NSC) may gain clinical benefit from ICIs, but irAEs in NSC patients are rarely examined. Therefore, our study systematically summarized reports of irAEs in NSC.

methodsWe obtained information from the FDA adverse event reporting system from the first quarter (Q1) of 2013 to the fourth quarter (Q4) of 2022. We examined use of a combination of ICIs and chemotherapy (ICI_Chemo) or chemotherapy only (ICI_Chemo) for patients with NSC. Multiple disproportionality analyses were applied to assess irAEs. Multiomics data from the gene expression omnibus (GEO) database were analyzed to explore potential molecular mechanisms associated with irAEs in NSC patients.

resultsFourteen irAEs were identified in 8,357 NSC patients after removing duplicates; the top five events were seizure, confused state, encephalopathy, muscular weakness and gait disturbance. Older patients were more likely to develop irAEs than were younger patients. From the start of ICIs_Chemo to irAE occurrence, there was a significant difference in the time to onset of irAEs between age groups. irAEs may occur via mechanisms involving the inflammatory response, secretion of inflammatory mediators, and aberrant activation of pathologic pathways.

conclusionsThis study helps to characterize irAEs in NSC patients treated with ICIs. We combined GEO database analysis to explore the potential molecular mechanisms of irAEs. The results of this study provide a basis for improving the toxic effects of ICIs in NSC patients.

Indexed as

Adverse Drug Reaction Reporting SystemsImmune Checkpoint InhibitorsUnited States Food and Drug AdministrationAdolescentAdultAgedAged, 80 and overDrug-Related Side Effects and Adverse ReactionsFemaleHumansMaleMiddle AgedUnited StatesYoung AdultImmune Checkpoint InhibitorsFDA adverse event reporting systemImmune checkpoint inhibitorsImmune-related adverse eventsNervous system cancerReal-world data

Identifiers

PMID39249163
PMCPMC11383843

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.